IDO Antibody (E-11): sc-365517
- IDO Antibody (E-11) is a mouse monoclonal IgM κ provided at 200 µg/ml
- specific for an epitope mapping between amino acids 11-35 near the N-terminus of IDO of mouse origin
- recommended for detection of IDO of mouse, rat and human origin by WB, IP, IF and ELISA
- See IDO (mIDO-48): sc-53978 for IDO antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for IDO Antibody (E-11). This work is in progress.
QUICK LINKS
IDO Antibody (E-11) is a mouse monoclonal IgM antibody that detects indoleamine 2,3-dioxygenase (IDO) in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). IDO is a crucial enzyme that catalyzes the degradation of the essential amino acid L-tryptophan into N-formylkynurenine, playing a significant role in immune regulation and tolerance. This enzymatic activity helps modulate immunological responses, protecting allogeneic concepti from alloreactive maternal lymphocytes, which is vital during pregnancy. IDO can inhibit T cell proliferation, as demonstrated in studies where IDO-transfected cells co-cultured with T cells resulted in reduced T cell activity. Additionally, IDO interaction with CD123-positive dendritic cells highlights its role in suppressing T cell responses, making IDO a potential target for therapeutic strategies aimed at modulating immune responses. Pharmacological or genetic manipulation of IDO may provide valuable insights into controlling undesirable T cell activity, offering new avenues for treatment in various immunological disorders.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
IDO Antibody (E-11) References:
- IDO and tolerance to tumors. | Munn, DH. and Mellor, AL. 2004. Trends Mol Med. 10: 15-8. PMID: 14720581
- IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment. | Munn, DH., et al. 2017. Cancer Immunol Immunother. 66: 1049-1058. PMID: 28488123
- Role of IDO and TDO in Cancers and Related Diseases and the Therapeutic Implications. | Ye, Z., et al. 2019. J Cancer. 10: 2771-2782. PMID: 31258785
- IDO and Kynurenine Metabolites in Peripheral and CNS Disorders. | Huang, YS., et al. 2020. Front Immunol. 11: 388. PMID: 32194572
- Blockade of IDO-Kynurenine-AhR Axis Ameliorated Colitis-Associated Colon Cancer via Inhibiting Immune Tolerance. | Zhang, X., et al. 2021. Cell Mol Gastroenterol Hepatol. 12: 1179-1199. PMID: 34087454
- Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma. | Zhai, L., et al. 2021. Clin Cancer Res. 27: 6514-6528. PMID: 34479957
- Novel Substituted Tetrahydroquinoline Compounds as Indoleamine-2,3-dioxygenase (IDO) Inhibitors. | Sabnis, RW. 2021. ACS Med Chem Lett. 12: 1524-1525. PMID: 34676029
- IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status. | Nandre, R., et al. 2022. Cancer Immunol Res. 10: 571-580. PMID: 35290437
- Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC. | Della Corte, CM., et al. 2022. J Transl Med. 20: 541. PMID: 36419183
- Dendritic cell-expressed IDO alleviates atherosclerosis by expanding CD4+CD25+Foxp3+Tregs through IDO-Kyn-AHR axis. | Wang, F., et al. 2023. Int Immunopharmacol. 116: 109758. PMID: 36706593
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IDO Antibody (E-11) | sc-365517 | 200 µg/ml | $322.00 | |||
IDO (E-11) Neutralizing Peptide | sc-365517 P | 100 µg/0.5 ml | $69.00 |